| Authors: |
Choueiri TK; Department of Medical Oncology, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA. Electronic address: toni_choueiri@dfci.harvard.edu., Larkin J; Renal and Skin Units, The Royal Marsden NHS Foundation Trust, Chelsea, London, UK., Pal S; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, USA., Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Rini BI; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, USA., Venugopal B; Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK., Alekseev B; P. Hertsen Moscow Oncology Research Institute, Moscow, Russia., Miyake H; Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan., Gravis G; Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Université, Inserm, CNRS, CRCM, Marseille, France., Bilen MA; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA., Hariharan S; Oncology, Pfizer, New York, USA., Chudnovsky A; Oncology, Pfizer, Cambridge, USA., Ching KA; Computational Biology, Pfizer, San Diego, USA., Mu XJ; Computational Biology, Pfizer, San Diego, USA., Mariani M; Immuno-Oncology, Pfizer, Milan, Lombardia, Italy., Robbins PB; Translational Oncology, Pfizer, San Diego, USA., Huang B; Biostatistics, Pfizer, Groton, USA., di Pietro A; Immuno-Oncology, Pfizer, Milan, Lombardia, Italy., Albiges L; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. |
